Novo Nordisk/Amgen/Kirin thrombopoietin venture
- Novo Nordisk has entered into an agreement with Amgen, Kirin and their joint venture Kirin-Amgen for the marketing and sale of thrombopoietin, a platelet growth factor thought to have potential in preventing bleeding complications in cancer chemotherapy patients. Terms state that Amgen and Kirin gain rights to market TPO under license from Novo. Financial terms were not disclosed. In June last year, researchers from ZymoGenetics, a unit of Novo, announced they had cloned TPO. Amgen-Kirin cloned the factor at around the same time. Novo is thought to have a strong proprietary position, as it has already filed several patent applications relating to TPO.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze